The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•20 April 2026•

1 min read

AB Science Reports Positive Long-Term Survival Data for Masitinib in ALS Patients

Key Facts

1Masitinib treatment showed a 5-year survival rate of 42.3%, representing a 2-fold improvement over historical benchmarks.

249% of long-term survivors maintained a satisfactory quality of life without the need for mechanical assistance.

AB Science SA has published new clinical data demonstrating significant long-term survival benefits for ALS patients treated with its drug candidate, masitinib. The findings, released on the medRxiv platform, show a 5-year survival rate of 42.3%, representing a twofold improvement over historical benchmarks. Notably, 49% of long-term survivors maintained a satisfactory quality of life without requiring mechanical assistance. The median overall survival reached 121 months for masitinib-treated patients, far exceeding the 42 months predicted by the ENCALS model. This positive clinical validation from the phase 2b/3 AB10015 study serves as a major catalyst for the company's valuation. Investors are closely monitoring these developments as the firm moves toward future regulatory milestones in the biotechnology sector.